CAROL CROUCH-ROSS: Open Payments
NPI 1053466946 · LIVONIA, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,725 in 150 payments from 16 companies in 2025. Trend: 2023 $4,046 · 2024 $3,781 · 2025 $4,725
Food & beverage: $4,718Education: $8
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 32 | $1,088 |
| Otsuka America Pharmaceutical, Inc. | 22 | $617 |
| Axsome Therapeutics, Inc. | 14 | $617 |
| Lundbeck LLC | 14 | $498 |
| Teva Pharmaceuticals USA, Inc. | 12 | $436 |
| E.R. Squibb & Sons, L.L.C. | 13 | $358 |
| ABBVIE INC. | 8 | $291 |
| Supernus Pharmaceuticals, Inc. | 16 | $269 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $117 |
Products named: REXULTI, CAPLYTA, Auvelity, AUSTEDO XR, VRAYLAR, Qelbree, COBENFY, TRINTELLIX.
Industry payments across MI — which companies pay providers there.
